ABBV vs. LLY, JNJ, MRK, PFE, BMY, ZTS, RPRX, JAZZ, CORT, and PRGO
Should you be buying AbbVie stock or one of its competitors? The main competitors of AbbVie include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.
AbbVie vs.
AbbVie (NYSE:ABBV) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, community ranking, earnings, profitability, institutional ownership, media sentiment, valuation and risk.
AbbVie has a beta of 0.58, meaning that its share price is 42% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.42, meaning that its share price is 58% less volatile than the S&P 500.
In the previous week, Eli Lilly and Company had 69 more articles in the media than AbbVie. MarketBeat recorded 157 mentions for Eli Lilly and Company and 88 mentions for AbbVie. AbbVie's average media sentiment score of 1.43 beat Eli Lilly and Company's score of 1.33 indicating that AbbVie is being referred to more favorably in the media.
AbbVie presently has a consensus target price of $208.35, indicating a potential upside of 3.13%. Eli Lilly and Company has a consensus target price of $1,007.94, indicating a potential upside of 15.31%. Given Eli Lilly and Company's higher possible upside, analysts clearly believe Eli Lilly and Company is more favorable than AbbVie.
70.2% of AbbVie shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.3% of AbbVie shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
AbbVie received 129 more outperform votes than Eli Lilly and Company when rated by MarketBeat users. Likewise, 73.43% of users gave AbbVie an outperform vote while only 70.67% of users gave Eli Lilly and Company an outperform vote.
Eli Lilly and Company has a net margin of 23.51% compared to AbbVie's net margin of 7.59%. AbbVie's return on equity of 296.28% beat Eli Lilly and Company's return on equity.
Eli Lilly and Company has lower revenue, but higher earnings than AbbVie. Eli Lilly and Company is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
AbbVie pays an annual dividend of $6.56 per share and has a dividend yield of 3.2%. Eli Lilly and Company pays an annual dividend of $6.00 per share and has a dividend yield of 0.7%. AbbVie pays out 273.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company pays out 51.2% of its earnings in the form of a dividend. AbbVie has raised its dividend for 53 consecutive years and Eli Lilly and Company has raised its dividend for 11 consecutive years. AbbVie is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Summary
AbbVie beats Eli Lilly and Company on 12 of the 21 factors compared between the two stocks.
Get AbbVie News Delivered to You Automatically
Sign up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
This page (NYSE:ABBV) was last updated on 2/21/2025 by MarketBeat.com Staff
Free ABBV Stock Alerts